Lexicon adds type 1 diabetes data to boost its dual SGLT1/2 inhibitor
This article was originally published in Scrip
Executive Summary
Lexicon Pharmaceuticals has announced positive top-line data for its dual SGLT1/2 inhibitor LX4211 in type 1 diabetes patients to add to the promising results seen in type 2 diabetes reported last October (scripintelligence.com, 2 October 2013).